Advertisement

Natural History, Pathogenesis, and Prevention of HCV Infection

  • Edgar D. Charles
  • Lynn B. Dustin
  • Charles M. Rice
Chapter

Abstract

Approximately 170 million people worldwide are chronically infected with hepatitis C virus (HCV), but most of these individuals are unaware of being infected. HCV is a major cause of liver-related morbidity and mortality, and it frequently causes extrahepatic manifestations of disease. This chapter considers the natural history, pathogenesis, and prevention of HCV. This positive strand RNA virus is transmitted by percutaneous or, in very rare circumstances, mucosal exposure to HCV-infected blood. Infection targets the hepatocytes, with resultant liver inflammation and eventual fibrosis. In a subset of individuals the hepatic disease will progress to cirrhosis, placing them at risk for hepatic decompensation and hepatocellular carcinoma. Extrahepatic manifestations are seen in 10–50% of HCV-infected persons, most commonly mixed cryoglobulinemia, which is fundamentally a B cell lymphoproliferative disorder. Some individuals develop B cell non-Hodgkin lymphoma, which is usually of low-grade, although more aggressive forms have been reported. Mixed cryoglobulinemia causes a small-vessel vasculitis, manifesting as palpable purpura, arthritis, membranoproliferative glomerulonephritis, and peripheral neuropathy. Extrahepatic signs and symptoms usually regress with successful eradication of HCV. The prevention of HCV rests upon the screening of individuals at highest risk for HCV infection, coupled with appropriate risk reduction strategies to reduce viral transmission and appropriate treatment of HCV infection to reduce the potentially infectious reservoir.

Keywords

Mixed Cryoglobulinemia Membranoproliferative Glomerulonephritis Porphyria Cutanea Tarda Splenic Marginal Zone Lymphoma Extrahepatic Manifestation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    WHO (1997) Hepatitis C: global prevalence. Wkly Epidemiol Rec 72:341–344Google Scholar
  2. 2.
    Frank C, Mohamed MK, Strickland GT, Lavanchy D et al (2000) The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355:887–891PubMedCrossRefGoogle Scholar
  3. 3.
    Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M et al (2000) Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 32:111–115PubMedCrossRefGoogle Scholar
  4. 4.
    Alter MJ (1997) Epidemiology of hepatitis C. Hepatology 26:62S–65SPubMedCrossRefGoogle Scholar
  5. 5.
    Armstrong GL, Alter MJ, McQuillan GM, Margolis HS (2000) The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 31:777–782PubMedCrossRefGoogle Scholar
  6. 6.
    van de Laar TJ, van der Bij AK, Prins M, Bruisten SM et al (2007) Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 196:230–238PubMedCrossRefGoogle Scholar
  7. 7.
    Danta M, Brown D, Bhagani S, Pybus OG et al (2007) Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 21:983–991PubMedCrossRefGoogle Scholar
  8. 8.
    Ohto H, Terazawa S, Sasaki N, Hino K et al (1994) Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 330:744–750PubMedCrossRefGoogle Scholar
  9. 9.
    Mast EE, Hwang LY, Seto DS, Nolte FS et al (2005) Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 192:1880–1889PubMedCrossRefGoogle Scholar
  10. 10.
    Mast EE, Alter MJ, Margolis HS (1999) Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 17:1730–1733PubMedCrossRefGoogle Scholar
  11. 11.
    (1999) Hepatitis C – global prevalence (update). Wkly Epidemiol Rec 74:425–427Google Scholar
  12. 12.
    Simmonds P (1999) Viral heterogeneity of the hepatitis C virus. J Hepatol 31(Suppl 1):54–60PubMedCrossRefGoogle Scholar
  13. 13.
    Simmonds P, Bukh J, Combet C et al (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962–973PubMedCrossRefGoogle Scholar
  14. 14.
    Bouchardeau F, Cantaloube JF, Chevaliez S et al (2007) Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 45:1140–1145PubMedCrossRefGoogle Scholar
  15. 15.
    Liu CH, Chen BF, Chen SC et al (2006) Selective transmission of hepatitis C virus quasi species through a needlestick accident in acute resolving hepatitis. Clin Infect Dis 42:1254–1259PubMedCrossRefGoogle Scholar
  16. 16.
    Quer J, Esteban JI, Cos J et al (2005) Effect of bottlenecking on evolution of the nonstructural protein 3 gene of hepatitis C virus during sexually transmitted acute resolving infection. J Virol 79:15131–15141PubMedCrossRefGoogle Scholar
  17. 17.
    Ray SC, Fanning L, Wang XH et al (2005) Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med 201:1753–1759PubMedCrossRefGoogle Scholar
  18. 18.
    Fan X, Mao Q, Zhou D et al (2009) High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. Hepatology 50:1765–1772PubMedCrossRefGoogle Scholar
  19. 19.
    Goodman ZD (2007) Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 47:598–607PubMedCrossRefGoogle Scholar
  20. 20.
    Farci P, Alter HJ, Wong D et al (1991) A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 325:98–104PubMedCrossRefGoogle Scholar
  21. 21.
    Courouce AM, Le Marrec N, Girault A et al (1994) Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of second- and third-generation anti-HCV assays. Transfusion 34:790–795PubMedCrossRefGoogle Scholar
  22. 22.
    Sulkowski MS, Ray SC, Thomas DL (2002) Needlestick transmission of hepatitis C. JAMA 287:2406–2413PubMedCrossRefGoogle Scholar
  23. 23.
    Netski DM, Mosbruger T, Depla E et al (2005) Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis 41:667–675PubMedCrossRefGoogle Scholar
  24. 24.
    Osburn WO, Fisher BE, Dowd KA et al (2009) Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138: 315–324PubMedCrossRefGoogle Scholar
  25. 25.
    Page K, Hahn JA, Evans J et al (2009) Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 200:1216–1226PubMedCrossRefGoogle Scholar
  26. 26.
    Thomas DL, Thio CL, Martin MP et al (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798–801PubMedCrossRefGoogle Scholar
  27. 27.
    Ge D, Fellay J, Thompson AJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399–401PubMedCrossRefGoogle Scholar
  28. 28.
    Fattovich G, Giustina G, Degos F et al (1997) Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112:463–472PubMedCrossRefGoogle Scholar
  29. 29.
    Seeff LB (2002) Natural history of chronic hepatitis C. Hepatology 36:S35–S46PubMedCrossRefGoogle Scholar
  30. 30.
    Kenny-Walsh E (1999) Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 340: 1228–1233PubMedCrossRefGoogle Scholar
  31. 31.
    Wiese M, Berr F, Lafrenz M et al (2000) Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 32:91–96PubMedCrossRefGoogle Scholar
  32. 32.
    Vogt M, Lang T, Frosner G et al (1999) Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 341:866–870PubMedCrossRefGoogle Scholar
  33. 33.
    Seeff LB, Miller RN, Rabkin CS et al (2000) 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 132:105–111PubMedCrossRefGoogle Scholar
  34. 34.
    Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825–832PubMedCrossRefGoogle Scholar
  35. 35.
    Kleter B, Brouwer JT, Nevens F et al (1998) Hepatitis C virus genotypes: epidemiological and clinical associations. Benelux Study Group on Treatment of Chronic Hepatitis C. Liver 18:32–38PubMedGoogle Scholar
  36. 36.
    Poynard T, Ratziu V, Charlotte F et al (2001) Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 34:730–739PubMedCrossRefGoogle Scholar
  37. 37.
    Graham CS, Baden LR, Yu E et al (2001) Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 33:562–569PubMedCrossRefGoogle Scholar
  38. 38.
    Macias J, Berenguer J, Japon MA et al (2009) Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 50:1056–1063PubMedCrossRefGoogle Scholar
  39. 39.
    Qurishi N, Kreuzberg C, Luchters G et al (2003) Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362:1708–1713PubMedCrossRefGoogle Scholar
  40. 40.
    Zarski JP, Bohn B, Bastie A et al (1998) Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 28:27–33PubMedCrossRefGoogle Scholar
  41. 41.
    Cacciola I, Pollicino T, Squadrito G et al (1999) Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 341:22–26PubMedCrossRefGoogle Scholar
  42. 42.
    Leandro G, Mangia A, Hui J et al (2006) Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130:1636–1642PubMedCrossRefGoogle Scholar
  43. 43.
    Gumber SC, Chopra S (1995) Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 123:615–620PubMedCrossRefGoogle Scholar
  44. 44.
    Zignego AL, Ferri C, Pileri SA et al (2007) Extrahepatic manifestations of hepatitis C virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 39:2–17PubMedCrossRefGoogle Scholar
  45. 45.
    Giordano TP, Henderson L, Landgren O et al (2007) Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 297:2010–2017PubMedCrossRefGoogle Scholar
  46. 46.
    Ferri C, Caracciolo F, Zignego AL et al (1994) Hepatitis C virus infection in patients with non-Hodgkin’s lymphoma. Br J Haematol 88:392–394PubMedCrossRefGoogle Scholar
  47. 47.
    Zuckerman E, Zuckerman T, Levine AM et al (1997) Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 127:423–428PubMedCrossRefGoogle Scholar
  48. 48.
    Talamini R, Montella M, Crovatto M et al (2004) Non-Hodgkin’s lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 110:380–385PubMedCrossRefGoogle Scholar
  49. 49.
    Matsuo K, Kusano A, Sugumar A et al (2004) Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 95:745–752PubMedCrossRefGoogle Scholar
  50. 50.
    De Vita S, De Re V, Gasparotto D et al (2000) Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum 43:94–102PubMedCrossRefGoogle Scholar
  51. 51.
    De Vita S, Sacco C, Sansonno D et al (1997) Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood 90:776–782PubMedGoogle Scholar
  52. 52.
    Misiani R, Bellavita P, Fenili D et al (1994) Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 330:751–756PubMedCrossRefGoogle Scholar
  53. 53.
    Hermine O, Lefrere F, Bronowicki JP et al (2002) Regression of splenic lymphoma with villous lymphocytes after ­treatment of hepatitis C virus infection. N Engl J Med 347:89–94PubMedCrossRefGoogle Scholar
  54. 54.
    Zuckerman E, Zuckerman T, Sahar D et al (2001) bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection. Br J Haematol 112:364–369PubMedCrossRefGoogle Scholar
  55. 55.
    Zignego AL, Ferri C, Giannelli F et al (2002) Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 137:571–580PubMedCrossRefGoogle Scholar
  56. 56.
    Libra M, Gloghini A, Malaponte G et al (2008) Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. J Hepatol 49:170–174PubMedCrossRefGoogle Scholar
  57. 57.
    Limpens J, Stad R, Vos C et al (1995) Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 85:2528–2536PubMedGoogle Scholar
  58. 58.
    Libra M, De Re V, De Vita S et al (2003) Low frequency of bcl-2 rearrangement in HCV-associated non-Hodgkin’s lymphoma tissue. Leukemia 17:1433–1436PubMedCrossRefGoogle Scholar
  59. 59.
    Agnello V, Chung RT, Kaplan LM (1992) A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 327:1490–1495PubMedCrossRefGoogle Scholar
  60. 60.
    Ferri C, Sebastiani M, Giuggioli D et al (2004) Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 33:355–374PubMedCrossRefGoogle Scholar
  61. 61.
    Dammacco F, Sansonno D, Piccoli C et al (2001) The cryoglobulins: an overview. Eur J Clin Invest 31:628–638PubMedCrossRefGoogle Scholar
  62. 62.
    Gorevic PD (1995) Cryopathies: cryoglobulins and cryofibrinogenimia. In: Frank MM, Austen KF, Claman HN (eds) Samter’s immunologic diseases. Little Brown, Boston, p 951Google Scholar
  63. 63.
    Charles ED, Dustin LB (2009) Hepatitis C virus-induced cryoglobulinemia. Kidney Int 76:818–824PubMedCrossRefGoogle Scholar
  64. 64.
    Brouet JC, Clauvel JP, Danon F et al (1974) Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57:775–788PubMedCrossRefGoogle Scholar
  65. 65.
    Agnello V (1997) The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol 19:111–129PubMedCrossRefGoogle Scholar
  66. 66.
    Sansonno D, Dammacco F (2005) Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 5:227–236PubMedCrossRefGoogle Scholar
  67. 67.
    Saadoun D, Landau DA, Calabrese LH, Cacoub PP (2007) Hepatitis C-associated mixed cryoglobulinaemia: a ­crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford) 46:1234–1242CrossRefGoogle Scholar
  68. 68.
    Johnson RJ, Gretch DR, Yamabe H et al (1993) Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328:465–470PubMedCrossRefGoogle Scholar
  69. 69.
    D’Amico G (1998) Renal involvement in hepatitis C ­infection: cryoglobulinemic glomerulonephritis. Kidney Int 54:650–671PubMedCrossRefGoogle Scholar
  70. 70.
    Authier FJ, Pawlotsky JM, Viard JP et al (1993) High incidence of hepatitis C virus infection in patients with cryoglobulinemic neuropathy. Ann Neurol 34:749–750PubMedCrossRefGoogle Scholar
  71. 71.
    Lonardo A, Adinolfi LE, Loria P et al (2004) Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 126:586–597PubMedCrossRefGoogle Scholar
  72. 72.
    Shengyuan L, Songpo Y, Wen W et al (2009) Hepatitis C virus and lichen planus: a reciprocal association determined by a meta-analysis. Arch Dermatol 145:1040–1047PubMedCrossRefGoogle Scholar
  73. 73.
    Cacoub P, Renou C, Rosenthal E et al (2000) Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d’Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C. Medicine (Baltimore) 79:47–56CrossRefGoogle Scholar
  74. 74.
    Hennessey KA, Kim AA, Griffin V et al (2009) Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States. J Urban Health 86:93–105PubMedCrossRefGoogle Scholar
  75. 75.
    McGovern BH, Wurcel A, Kim AY et al (2006) Acute hepatitis C virus infection in incarcerated injection drug users. Clin Infect Dis 42:1663–1670PubMedCrossRefGoogle Scholar
  76. 76.
    (1998) Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for disease control and prevention. MMWR Recomm Rep 47:1–39Google Scholar
  77. 77.
    Heathcote EJ (2007) Antiviral therapy: chronic hepatitis C. J Viral Hepat 14(Suppl 1):82–88PubMedCrossRefGoogle Scholar
  78. 78.
    Meier V, Ramadori G (2009) Hepatitis C virus virology and new treatment targets. Expert Rev Anti Infect Ther 7:329–350PubMedCrossRefGoogle Scholar
  79. 79.
    U.S. Public Health Service (2001) Updated U.S. public health service guidelines for the management of ­occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 50:1–52Google Scholar

Copyright information

© Springer-Verlag Italia 2012

Authors and Affiliations

  • Edgar D. Charles
    • 1
  • Lynn B. Dustin
    • 1
  • Charles M. Rice
    • 1
  1. 1.Center for the Study of Hepatitis C, Laboratory of Virology and Infectious DiseaseThe Rockefeller UniversityNew YorkUSA

Personalised recommendations